Exposure to antibiotics following FMT may lead to recurrent CDI, suggesting the need for modified strategies to prevent recurrent CDI in some patients.

UTIs are among the most common infections worldwide, affecting some 15 million women a year. Phenazopyridine, sold under brand names such as Azo and Uristat, is used to treat the pain, burning and ...

Spero Therapeutics, Inc. (NASDAQ: SPRO) saw its stock surge by 240% on May 28 following the company’s announcement of the ...

Half the inks tested in a study contained polyethylene glycol, which can cause organ damage with repeated exposure. Some ...

Learn how to prevent urinary tract infections (UTIs) with simple daily habits. Discover hygiene tips, hydration advice, diet ...

GSK and Spero Therapeutics’ Phase III trial of their oral antibiotic for complicated urinary tract infections (cUTI) will end ...

Gepotidacin was non-inferior to ceftriaxone plus azithromycin for the primary outcome of microbiological success. 2. There were no serious or treatment-related adverse events in either group. Evidence ...

Shares of Spero Therapeutics gained after the company and GSK ended their trial for a treatment for complicated urinary tract infections early after it met its primary endpoint. The stock more than ...

Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

British pharmaceutical company GSK PLC (GSK) and its Massachusetts-based partner Spero Therapeutics (SPRO) said on Wednesday ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

GSK Plc halted a trial following positive results for an oral antibiotic to treat complicated urinary tract infections that could replace an intravenous medicine that is typically used.